Study Title
Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression

Michal Schnaider Beeri, PhD
Joshua Sonnen, MD


Despite great scientific efforts to find treatments for Alzheimer disease (AD), only 5 medications are marketed, with limited beneficial effects on symptoms, on a limited proportion of patients, without modification of the disease course. The prevalence of AD doubles every 5 years, reaching the alarming rate of 50% in those aged 85 years and older. In the context of the demographic trends of modern society, where the elderly are the fastest growing segment of the population, identification of new therapeutic targets that may prevent, delay, or cure AD is critically needed. here is some of the abstract < this is some of the abstract i was told it does not work > but seems to work for me

January 27, 2016
View study

Share This

Related Topics


Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD